Several analysts have recently updated their ratings and price targets for Aptevo Therapeutics (NASDAQ: APVO):
- 11/24/2025 – Aptevo Therapeutics had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
- 11/17/2025 – Aptevo Therapeutics had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
- 11/11/2025 – Aptevo Therapeutics had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
- 11/5/2025 – Aptevo Therapeutics had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
- 10/8/2025 – Aptevo Therapeutics had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
- 9/27/2025 – Aptevo Therapeutics had its “sell (e)” rating reaffirmed by analysts at Weiss Ratings.
Aptevo Therapeutics Inc, a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells.
See Also
- Five stocks we like better than Aptevo Therapeutics
- Retail Stocks Investing, Explained
- Why Gold Loves Trump as Much as Trump Loves Gold
- What is the Euro STOXX 50 Index?
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Short Selling – The Pros and Cons
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for Aptevo Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
